We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Consolidation Trend in European LIMS Market

By HospiMedica staff writers
Posted on 22 Jan 2006
Print article
Consolidation is an increasing trend in western European laboratory information management systems (LIMS), as LIMS vendors seek to strengthen their product lines through mergers and acquisitions and co-marketing agreements. Revenues in this LIMS market are forecast to increase from U.S.$90 million in 2005 to $163.4 million in 2012, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), an international consulting company.

Strategic partnerships can help vendors create more customer-driven, value-added product portfolios that can help expand the scope of LIMS, achieving high throughput that will aid the lead screening of pharmaceutical companies. However, consolidations bring together multiple solutions developed by various vendors, which forces an acquiring company to link various systems and streamline the communication between them while minimizing technical incompatibilities.

Therefore, a key challenge for LIMS vendors is to develop an open, standardized technology platform to ease end users' difficulties in understanding the technicalities of solution design and help them reduce training costs. As customers show increased demand for configurable off-the-shelf solutions that address their specific needs, the LIMS market is likely to progress from customization to configurability. This ensures a wide range of flexible solutions and offers venders an opportunity to add value to their product lines and thereby achieve strong product differentiation.

Vendors with good brand recognition will be able to penetrate the pharmaceutical user base with greater ease than new niche market participants. Besides, pharmaceutical companies tend to prefer vendors that have a proven history of efficient installations. However, unfavorable return-on-investment (ROI) and the existence of legacy systems could pose entry barriers to LIMS vendors.
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fixed Speed Tube Rocker
GTR-FS
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.